Literature DB >> 8636090

Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization.

P A Harding1, X Wang, S Okada, W Y Chen, W Wan, J J Kopchick.   

Abstract

It has previously been shown that a human growth hormone (hGH) analog, hGH-G120R, acts as a GH antagonist (Chen, W. Y., Wight, D. C. , Wagner, T. E., and Kopchick, J. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5061-5065; Chen, W. Y., White, M. E., Wagner, T. E., and Kopchick, J. J. (1991) Endocrinology 129, 1402-1408; Chen, W. Y., Chen, N-Y., Yun, J., Wang, X. Z., Wagner, T. E., and Kopchick, J. J. (1994) J. Biol. Chem. 269, 15892-15897). In this study, we report the ability of hGH and hGH-G120R to be internalized by GH receptor expressing cells. Additionally, results of chemical cross-linking experiments revealed that both native hGH and hGH-G120R form complexes similar in size to that expected for hGH when bound to recombinant hGH-binding protein (bp). The molecular mass of the complex was determined to be approximately 280 kDa which is consistent with multiple receptors interacting with the ligand. The predominant radiolabeled band detected was a complex of approximately 140 kDa which probably represents one GH molecule bound to one GH receptor. The cross-linked complexes were not detected in the presence of excess unlabeled hGH or hGH-G120R and were not observed in cells which do not express detectable levels of GH receptors. Also, GH induced tyrosine phosphorylation of a complex of proteins of approximately 95 kDa in these cells whereas hGH-G120R did not. Thus, we have separated the hGH or hGH-G120R/GHR binding and internalization capabilities from the ability to stimulate tyrosine phosphorylation of intracellular proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636090     DOI: 10.1074/jbc.271.12.6708

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer.

Authors:  Weijie Zhang; Pengxu Qian; Xiao Zhang; Min Zhang; Hong Wang; Mingming Wu; Xiangjun Kong; Sheng Tan; Keshuo Ding; Jo K Perry; Zhengsheng Wu; Yuan Cao; Peter E Lobie; Tao Zhu
Journal:  J Biol Chem       Date:  2015-04-14       Impact factor: 5.157

2.  Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis.

Authors:  Jürgen Gent; Peter van Kerkhof; Marcel Roza; Guojun Bu; Ger J Strous
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

3.  Distinct endocytic responses of heteromeric and homomeric transforming growth factor beta receptors.

Authors:  R A Anders; S L Arline; J J Doré; E B Leof
Journal:  Mol Biol Cell       Date:  1997-11       Impact factor: 4.138

Review 4.  Rational design of competitive prolactin/growth hormone receptor antagonists.

Authors:  Estelle Tallet; Vincent Rouet; Jean-Baptiste Jomain; Paul A Kelly; Sophie Bernichtein; Vincent Goffin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

5.  Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production.

Authors:  Hayden-William Courtland; Hui Sun; Mordechay Beth-On; Yingjie Wu; Sebastien Elis; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2011-04       Impact factor: 6.741

Review 6.  Prolactin receptor antagonists.

Authors:  C B Kuo; D Coss; A M Walker
Journal:  Endocrine       Date:  1998-10       Impact factor: 3.925

7.  Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.

Authors:  Reetobrata Basu; Shiyong Wu; John J Kopchick
Journal:  Oncotarget       Date:  2017-03-28

8.  Preparation of a Growth Hormone Receptor/Prolactin Receptor Bispecific Antibody Antagonist Which Exhibited Anti-Cancer Activity.

Authors:  Xin Chen; Di Wu; Yan Zheng; Xingxing Liu; Jianmeng Wang
Journal:  Front Pharmacol       Date:  2020-12-10       Impact factor: 5.810

Review 9.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.